嘿,我跟你说,可能未来医药界的一匹黑马已经出现了,他们说不定已经找到了艾滋病的治疗方法,甚至可能还有其他疾病的解药。
商业律师
5 回答
Okay, so I've been digging into this company, Enzolytics (ENZC), and it looks like they might be the real deal. Here's the gist:
* **Unicorn Status:** They're tackling COVID and HIV with some seriously impressive tech.
* **COVID Play:** They've got a proprietary method for creating monoclonal antibodies that could work on all variants because they target the unchangeable parts of the virus.
* **HIV Cure?:** They're developing therapies that might actually cure HIV-1, which no one else has been able to do.
* **Pipeline:** Plus, they've got a whole pipeline of other stuff in the works.
* **Huge Market:** We're talking about markets worth billions.
**The Key Players:**
* **Charles Cotropia (CEO):** Patent lawyer and brother to Joseph.
* **Joseph Cotropia (Chief Medical Officer):** The brains behind Clone 3.
* **Harry Zhabilov (CSO):** Inventor of ITV-1.
**What They Do:**
They're all about immunotherapy, focusing on HIV, COVID, and other retroviral diseases. Their main products are Clone 3 and ITV-1 for HIV, with more in development.
**Why This Matters:**
Immunotherapy is better than traditional treatments because it's more targeted and has fewer side effects.
**The Products:**
* **ITV-1:** Boosts antibody effectiveness.
* **Clone 3:** A monoclonal antibody that stops HIV from reproducing. It targets a constant "Achilles heel" on the virus.
* **Pipeline:** They're working on similar antibodies for CoronaVirus.
**The Goal:**
Combine ITV-1 and Clone 3 to cure HIV, get FDA approval, and mass-produce the cure.
**The Backstory (Clone 3):**
Clone 3 was discovered in 1989 but struggled to gain traction because it was a new approach. Even after the U.S. government confirmed its effectiveness, it was never brought to the public. Some think this is because it would disrupt the market for existing HIV drugs.
**Catalysts to watch for:**
* Government Funding
* SARS-CoV-2 mAbs completion
* Patent approvals
* New website
* FDA approvals
* Partnerships with big pharma
* Research into other diseases
* Uplisting to OTCQB/NASDAQ
**My Take:**
Enzolytics is doing cutting-edge biotech. With their leadership, technology, and access to labs, they're poised to make a big impact on global health and shareholder value.
**Disclaimer:** This is a long-term play for me. I'm holding this stock for a long, long time.